Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine - Test2 - elhamkhani - TriplyDB

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

http://www.wikidata.org/entity/Q26767415

about

Recent advances in the biology of human circulating tumour cells and metastasis Should tissue structure suppress or amplify selection to minimize cancer risk?Rational design of non-resistant targeted cancer therapies A novel method for RNA extraction from FFPE samples reveals significant differences in biomarker expression between orthotopic and subcutaneous pancreatic cancer patient-derived xenografts.Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.Differential selective pressure alters rate of drug resistance acquisition in heterogeneous tumor populations.Computational Methods for Characterizing Cancer Mutational Heterogeneity.ALK gene alterations in cancer: biological aspects and therapeutic implications.Homeostasis Back and Forth: An Ecoevolutionary Perspective of Cancer.Clonal cooperativity in heterogenous cancers.Measuring cancer evolution from the genome.Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap.Clonal evolution of chemotherapy-resistant urothelial carcinoma.Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf-/- mouse model.Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer Classifying the evolutionary and ecological features of neoplasms.Cancer Progression Models and Fitness Landscapes: a Many-to-Many Relationship.Progress and challenges of sequencing and analyzing circulating tumor cells.Multilevel, Dynamic Chronic Obstructive Pulmonary Disease Heterogeneity. A Challenge for Personalized Medicine.An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.Metastasis seeding cells: Lone invaders or mass migrators?Mitochondrial Metabolism: Yin and Yang for Tumor Progression.Transcriptome evolution from breast epithelial cells to basal-like tumors.Citrullinated α-enolase is an effective target for anti-cancer immunity.Changing mutational and adaptive landscapes and the genesis of cancer.Clinicopathological analysis of polyploid diffuse large B-cell lymphoma.DNA methylation profiling opens a new phase in the search of targeted therapy against Ewing sarcoma.Predicting evolution.Cutaneous Papillomaviruses and Non-melanoma Skin Cancer: Causal Agents or Innocent Bystanders?Addressing the challenges of applying precision oncology.Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance

P2860

Q28070120-8E9D2426-2190-4159-ADDE-1BB7D4ED6E2B Q28597478-DE9835A4-0B04-4846-94A5-66B5995F6CF5 Q33594692-BA9805A9-494E-4A4F-99A6-D43FCDA555B7 Q36125108-23FACEB7-957C-40CE-B0F1-EE06C577AEB3 Q36192083-A951205F-13FA-4705-AA5F-0BF2688A2034 Q37397222-7179C981-80B9-4CE3-8B16-966D46E8962D Q38703541-38445E29-F23A-4401-83AF-C765D9E3829E Q38767006-B2860251-795C-47F9-8F44-87230691167F Q38910371-16F79916-8F6D-4C40-8639-5BCD6C204324 Q38943125-3B3E3629-0669-46F0-B149-55EAD97C085C Q38980681-73F8997C-7D72-463D-968A-83E141AF6557 Q39441390-791FB6CF-B970-4F9D-A114-46A00DFC3BD7 Q41315076-707395D9-99C0-49FF-A2DF-F7815234346D Q41710165-3DF8EB95-1E0B-4B03-B66D-D40ED6647369 Q42087584-50403077-68E8-4DF0-AECD-3626482C6A48 Q45067426-199D1945-C285-40D6-9EF4-0528FC8F0FCF Q47313036-0475D0FD-2E9F-4F7A-BB24-114BC37F890A Q47425176-EE7C94E4-9085-4EBA-8D00-F4743A8CFB1B Q48013951-2B904721-3E70-4579-8F9E-50EB2E7A2149 Q48115878-F3A36A46-CCC8-454A-85AC-9F9DDA918E4B Q49546284-4AF4E5B5-AAFC-44B5-ABDE-930FBFA87B36 Q49918002-2850F63F-BD6E-4142-A92D-8F5CC0D26AB9 Q50128372-09563DF9-F272-41EE-AE36-FA2D33192656 Q50545407-E0CF00D5-84B1-415C-BA9F-BDE2CDA1ECA5 Q50908461-A1002DE7-04B1-4739-A331-879E18A46813 Q52594128-7E289623-6360-401B-955C-78BC6C38504C Q53834599-B74EBBCF-E917-49F5-8AC1-3052184B5CF9 Q54295384-EC1EAC67-5CBC-4A4C-BE67-832DE1A6DCF0 Q55054189-E2601955-2CB5-4529-9D74-EB744FD07BD0 Q55314165-242B2DEA-2341-4EDA-AC8A-EE405050D6F6 Q58802587-5F653F70-0C49-4317-A25E-E45895357B4E

P2860

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

http://www.wikidata.org/entity/Q26767415

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@ast

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@en

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@nl

type

label

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@ast

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@en

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@nl

prefLabel

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@ast

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@en

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@nl

P1433

Q26767415-F8B0FE79-840C-4AA0-9FA0-7D1C06A7E0F8

P1476

Q26767415-13DE2634-5F50-4979-8B1D-029CF1F3744B

P2093

Q26767415-06E1B629-AB1B-4F00-A9C9-0A9B1F9B3EC6

Q26767415-8C8AFC39-916B-4523-B2D8-755383F07C23

Q26767415-D14539E2-5DD0-4B41-957E-2ED642F5EE47

P2860

Q26767415-014606A7-9D4B-464C-A3CD-DA689968321D

Q26767415-0724186D-476C-4FC0-8288-EB07EE2B708D

Q26767415-0893E9FA-C7CD-4F45-B3BA-6A46081B8603

Q26767415-09AF3DAA-20AC-4BE9-BF52-68BB04AA590C

Q26767415-09EAD034-E8C5-466B-9F98-484305BE8F67

Q26767415-0C908E94-11BE-41F5-ACFF-4AEC0FB52EC9

Q26767415-15F81EB9-4738-4F0B-8EB1-6B8A611035A9

Q26767415-1C995FA1-2015-4170-BC85-DA24A68F516A

Q26767415-1DCB96D1-4753-4094-96A8-E9EA8D023CC8

Q26767415-23183736-87FF-4BC8-9232-9AAF01B20591

P304

Q26767415-DD13E22F-E536-43C4-8484-F40BFB503C7D

P31

Q26767415-95D37A61-B937-4631-8F9E-A7FC3D8DDEE3

P3181

Q26767415-15507C83-1A05-4800-B562-CE42F2E7F5CD

P356

Q26767415-4013A7A1-9771-49F5-9F6B-F4D4A729A3D0

P433

Q26767415-86148D87-DD0E-4364-8E4C-A3A0AE07E062

P478

Q26767415-8A784352-F659-42C1-AA4B-F29CED1F1DC6

P50

Q26767415-0B62D5DB-2236-47AB-B9FC-69EBAB5DD1BC

Q26767415-605E587D-C177-4AE5-AD30-376D5B349F17

Q26767415-82D52E29-62E7-4920-9D62-7F7F299C72A0

P577

Q26767415-1E92DFCB-BEA3-44BC-9F47-9F159AEC1D74

P5875

Q26767415-AE330EA0-23C9-4D1B-812F-D5EC02613F56

P698

Q26767415-1092C4C8-ADFE-42B7-98AD-2C6E32E0F8DB

P932

Q26767415-F4E6A247-917F-4DCD-BB34-5743AF805D5B

P3181

P356

J.TRECAN.2015.11.003

P1433

Trends in cancer

P1476

Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine

@en

P2093

Kamil A Lipinski

http://www.w3.org/2001/XMLSchema#string

Matthew Ashenden

http://www.w3.org/2001/XMLSchema#string

Matthew N Davies

http://www.w3.org/2001/XMLSchema#string

P2860

Evolutionary dynamics of cancer in response to targeted combination therapy

Quantifying the adaptive potential of an antibiotic resistance enzyme

Historical contingency and the evolution of a key innovation in an experimental population of Escherichia coli

Mutational processes molding the genomes of 21 breast cancers

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

Massive genomic rearrangement acquired in a single catastrophic event during cancer development

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

P304

49-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2575881

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.TRECAN.2015.11.003

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Marco Gerlinger

Andrea Sottoriva

Louise J Barber

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292346746

http://www.w3.org/2001/XMLSchema#string

P698

26949746

http://www.w3.org/2001/XMLSchema#string

P932

4756277

http://www.w3.org/2001/XMLSchema#string